66th ASH Annual Meeting: 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster III

Symposia: Cellular Immunotherapies other than CAR-T Cells: Basic and Translational Oral and Poster Abstracts
Poster

Research, Acute Myeloid Malignancies, AML, Fundamental Science, Translational Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Hematopoiesis, GVHD, Diseases, Immune Disorders, Immune mechanism, Treatment Considerations, Biological therapies, Immunology, Lymphoid Malignancies, Biological Processes, Myeloid Malignancies, Emerging technologies, Technology and Procedures, Gene editing, Miscellaneous Cellular Therapies, Natural Killer (NK) Cell Therapies, Imaging, Transplantation (Allogeneic and Autologous)

Halls G-H (San Diego Convention Center)

4811

Preclinical Study of HLA Class I-Edited Allogeneic iPSC-Derived Virus-Specific T Cells Targeting Epstein-Barr Virus-Associated Lymphomas

Kosuke Matsuzaki¹^*, Midori Ishii¹^*, Shintaro Kinoshita¹^*, Ayaka Goto¹^*, Yoko Azusawa²^*, Yoshiki Furukawa¹^*, Jun Ando^1,2^*, Hiromitsu Nakauchi^3,4^* and Miki Ando¹

¹Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan
²Division of Cell Therapy & Blood Transfusion Medicine, Juntendo University School of Medicine, Tokyo, Japan
³Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford
⁴Stem Cell Therapy Laboratory, Advanced Research Institute, Tokyo Medical and Dental University, Tokyo, Japan

4812

CD47-CD138 Bispecific Antibody Exhibits Selective Targeting of Multiple Myeloma

Maday Galeana Figueroa, MSc¹^*, Kishan Nyati, PhD¹^*, Tarang Sharma²^*, Binod Dhakal, MBBS¹, Meera Mohan, MD¹, Parameswaran N. Hari, MD, MBBS¹ and Sabarinath Venniyil Radhakrishnan, MD, MBBS¹

¹Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
²Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Wauwatosa, WI

4813

A Spatial Atlas of Human Gastro-Intestinal Acute Gvhd Reveals Epithelial and Immune Dynamics Underlying Disease Pathophysiology

Idan Milo¹^*, Nofar Azulay¹^*, Yuval Bussi¹^*, Raz Ben Uri¹^*, Tal Keidar-Haran²^*, Michal Eldar¹^*, Ofer Elhanani¹^*, Yotam Harnik¹^*, Oran Yakubovsky^1,3,4^*, Ido Nachmany³^*, Tomer Salame⁵^*, Philippe Bertheau⁶^*, David Michonneau, MD, PhD⁷^*, Gerard Socie^8,9 and Leeat Keren¹^*

¹Department of Molecular Cell Biology, Weizmann Institute of science, Rehovot, Israel
²Department of Pathology, Hadassah Medical Center, Rehovot, Israel
³Department of General Surgery and Transplantation, Sheba Medical Center, Ramat Gan, Israel
⁴Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
⁵Weizmann Institute of Science, Rehovot, ISR
⁶Hosp Saint-Louis, Paris, FRA
⁷Hematology and transplantation, Saint-Louis Hospital, APHP, Paris, France
⁸Hematology Transplantation, Paris, France
⁹INSERM UMR 976, Institut de Recherche Saint-Louis, Paris, France

4814

Bone Marrow Stromal Cells Hamper Leukemia Cell Induced NK Cell Activation and Cytotoxicity

Salomé Decombis^1,2,3^*, Johannes Smolander, PhD^1,2,3^*, Jonas Bouhlal, MSc, BSc^1,2,3^*, Jay Klievink, M.Sc^1,2,3^*, Hanna Lähteenmäki, MSc^1,2,3^*, Emmi Jokinen^1,2,3^*, Linh Lin^2,3^*, Hanna Laitinen^2,3^*, Konstantin Matjusinski^1,2,3^*, Eveliina Holappa^1,2,3^*, Mikko Myllymäki, MD, PhD^1,2,3, Heidi Haikala, PhD^2,3^*, Sara Gandolfi, MD, PhD^1,2,3^* and Satu Mustjoki, MD, PhD^1,2,3

¹Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
²Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
³ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland

4815

Characterizing the Role of Interferon-γ Signaling in Natural Killer Cell Dysfunction in Venetoclax-Resistant Acute Myeloid Leukemia

Daniel J. Chandra, MD^1,2, Faith Burns¹^*, Austin Nguyen, PhD³^*, Elias Pavlatos, PhD³^*, Khauan Bainha³^*, Nicola Long¹^*, Yoko Kosaka, PhD¹^*, Jessica Mulkey¹^*, Joanna Pucilowska, PhD³^*, Evan F. Lind, PhD¹, Jeffrey W. Tyner, PhD¹ and Jennifer N. Saultz, DO¹

¹Knight Cancer Institute, Oregon Health & Science University, Portland, OR
²Division of Hematology/Medical Oncology, Oregon Health & Science University, Portland, OR
³Knight Cancer Institute, Immune Monitoring and Cancer Omics Services, Portland, OR

4816

Co-Expression of IL-15 and CCL21 Strengthens CAR-NK Cells to Eliminate Tumors in Concert with T Cells and Equips Them with Higher PI3K/AKT/mTOR Signal Signature

Xindi Wang¹^*, Wenjing Luo¹^*, Zhaozhao Chen¹^*, Yu Hu^1,2^* and Heng Mei^1,2^*

¹Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
²Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China

4817

Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine

Kathrine S Rallis, MBBS, MSc¹, Jessica Liegel, MD², Giulia Cheloni, PhD³^*, Poorva Bindal, MD², Isabella Saldarriaga, BS³^*, Junyan Zhang²^*, Georges Chedid, MD²^*, Joseph Abirached, BS²^*, Jonah Lee, BS²^*, John G. Clohessy, PhD²^*, Samprity Ankita, BS²^*, Rajeev Relangi, BS²^*, Lina Bisharat, MS²^*, Hazal Toros, MS²^*, Sophia Adamia, PhD², Jasper B Lee, AB⁴^*, Donald Kufe, MD⁴^*, Kai W Wucherpfennig, MD, PhD⁴^*, Jacalyn Rosenblatt, MD³ and David Avigan, MD³

¹Beth Israel Deaconess Medical Center, Harvard Medical School, Brookline, MA
²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
³Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA
⁴Dana Farber Cancer Institute, Harvard Medical School, Boston, MA

4818

Cord-Derived Invariant Natural Killer T Cells As Novel Cell Therapy to Improve the Outcome of Hematopoietic Stem Cell Transplantation

Abel Trujillo-Ocampo¹^*, Maison Grefe¹^*, Pamella Borges²^*, Jelita Clinton³^*, Hong He, MD, PhD⁴^*, Dan Li, PhD⁵^*, Ling Yu⁶^*, Martiela Vaz de Freitas⁷^*, Lisa St. John, PhD⁶^*, Karen Clise-Dwyer, PhD⁸^*, Gheath Alatrash, PhD, DO⁹, Dinler Amaral Antues¹⁰^*, Qing Ma, PhD¹¹^*, Jeffrey J. Molldrem, MD¹², Elizabeth J. Shpall, MD¹³ and Jin S. Im, MD, PhD¹³

¹The University of Texas MD Anderson Cancer Center, Department of Hematopoietic Biology and Malignancy, Houston, TX
²University of Houston, Department of Biology and Biochemistry, Houston
³The University of Texas MD Anderson Cancer Center, Department of Hematopoietic Biology and Malignancy, Houston
⁴Department of Hematopoietic Biology and Malignancy, University of Texas M.D. Anderson Cancer Center, Houston, TX
⁵University of Texas M.D. Anderson Cancer Center, Department of Hematopoietic Biology and Malignancy, Houston, TX
⁶Department of Hematopoietic Biology and Malignancy, University of Texas M. D. Anderson Cancer Center, Houston, TX
⁷the University of Houston, Department of Biology and Biochemistry, Houston, TX
⁸Department of Hematopoietic Biology & Malignancy, The University of Texas M.D. Anderson Cancer Center, Houston
⁹Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Pearland, TX
¹⁰The University of Houston, Department of Biology and Biochemistry, Houston, TX
¹¹Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
¹²Departments of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
¹³Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

4819

Successful Generation of iPSC-Derived CD4⁺ and CD8⁺ CAR T Cells with Αβ-like T Cell Function, Including Antigen-Dependent Expansion and IL-2 Production

Dar Heinze, MD¹^*, Killian Sottoriva, PhD¹^*, Kristen Dettloff¹^*, Melissa Chin¹^*, Justin Gallagher¹^*, Alexa Galuppo¹^*, Kristen Fread, PhD¹^*, Justin Fang¹^*, Ryan Hasselkus²^*, Sarah Thomas¹^*, Eric Ma, PhD²^*, Ynes Helou, PhD¹^*, David Bauer, PhD¹^*, Jonathan Kurtz, PhD¹^*, Dustin Whitney, PhD¹^*, Chad Cowan, PhD²^* and G. Grant Welstead, PhD¹

¹Century Therapeutics, Boston, MA
²Clade Therapeutics, Boston, MA

4820

Leveraging Stage-Specific Promoters to Enhance Immune Cell Engineering in iPSC-Derived Cells for Cancer Immunotherapy

Arina Perez^*, Matthew S Hall, PhD^*, Sumei Lu, BSc^*, Brad Peterka, MSc^*, Michael Naso, Ph.D.^*, Hy Levitsky, MD and Buddha Gurung, Ph.D.^*

Century Therapeutics, Philadelphia, PA

4821

Universal Cloaking of Allogeneic T Cell Therapies Against Natural Killer Cells Via CD300a Agonism

G. Grant Welstead, PhD¹, Shuqi Zhang, PhD²^*, Justin Fang¹^*, Faith Thomas²^*, Andriana Lebid, Ph.D.³^*, Mike Miller, B.S.³^*, Daniel Perry, Ph.D.³^*, Dustin Whitney, PhD¹^*, Jill Carton³^*, Jonathan Kurtz, PhD¹^* and Chad Cowan, PhD²^*

¹Century Therapeutics, Boston, MA
²Clade Therapeutics, Boston, MA
³Century Therapeutics, Philadelphia, PA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH